Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Lauenstein, Ann Sophie ^a   Stettner, Mark ^b   Kieseier, Bernd C ^b   Lensch, Eckart ^a  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; NATALIZUMAB; RITUXIMAB; TOCILIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CEREBELLUM INJURY; CEREBROSPINAL FLUID CYTOLOGY; DIPLOPIA; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HICCUP; HUMAN; INTERNUCLEAR OPHTHALMOPLEGIA; LIMB DYSESTHESIA; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PARESTHESIA; PLASMAPHERESIS; PLEOCYTOSIS; PRIORITY JOURNAL; QUADRIPLEGIA; REMISSION; SPINAL CORD DISEASE; SPINAL CORD LESION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 84898656660     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-202939     Document Type: Article

References (15)

1. Bukhari W, Barnett MH, Prain K, et al. Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci 2012;13: 12970-93.
2. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66: 1485-9. (Pubitemid 43958540)
3. Kim SH, Kim W, Huh SY, et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol Seoul Korea 2013;9: 36-42.
4. Okamoto T, Ogawa M, Lin Y, et al. Treatment of neuromyelitis optica: current debate. Ther Adv Neurol Disord 2008;1: 5-12.
5. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63: 957-63. (Pubitemid 44036296)
6. Cree BAC, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64: 1270-2.
7. Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 2008;255: 305-7.
8. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69: 239-45.
9. Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012;79: 1065-6.
10. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108: 3701-6.
11. Venkiteshwaran A. Tocilizumab. MAbs 2009;1: 432-8.
12. Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol Jpn Rheum Assoc 2013;23: 827-31.
13. Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013;70: 390-3.
14. Rothhammer V, Heink S, Petermann F, et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med 2011;208: 2465-76.
15. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12: 554-62.